November 8, 2017 09:27 AM EST
Financing

Ger­man biotech In­flaRx rais­es $100M in IPO

Brittany Meiling

In­flaRx, a Ger­man bio­phar­ma de­vel­op­ing drugs for rare dis­eases, has raised $100 mil­lion in the in­dus­try’s third IPO this month.

The com­pa­ny sold 6.7 mil­lion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times